Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease
Sankar D. Navaneethan(Baylor College of Medicine), Joseph V. Nally(Cleveland Clinic), Sagar Jolly(Cleveland Clinic), G. Neil Thomas(Cleveland Clinic), Susana Arrigain(Cleveland Clinic), Mark J. Sarnak(Tufts Medical Center), Martin J. Schreiber(Cleveland Clinic), Emilio D. Poggio(Cleveland Clinic), Jesse D. Schold(Colorado School of Public Health)
Cited by 20
Related Papers
Heart Disease and Stroke Statistics—2021 Update
|Circulation|2021|5.7k
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data
|The Lancet Diabetes & Endocrinology|2015|897
Chronic Kidney Disease and Coronary Artery Disease
|Journal of the American College of Cardiology|2019|716